LEXICON PHARMACEUTICALS, INC. Restructuring Costs
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Restructuring Costs of $5.70 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2015-03-12
- LEXICON PHARMACEUTICALS, INC. restructuring costs for the quarter ending 2014-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. restructuring costs for fiscal 2014 was $5.70M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 9 month | Restructuring Costs 12 month |
|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $5.70M 10-K · filed 2015-03-12 | |
| 2014-09-30 | $5.70M 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |